EpiSwitch® Covid Severity Test (CST) - An advanced test for understanding your individual risk of severe illness due to COVID-19.
EpiSwitch CST is the first and only commercially available blood test to predict COVID-19 severity in ANY adult, independent of COVID-19 status.
Understanding the risk of a severe immune response and the potential for hospitalization is key for physicians to guide a strategy for avoiding infection and to make treatment decisions when necessary.
HOW TO ORDER
HOW TO ORDER
Personalize your guidance for each patient.
The EpiSwitch CST report includes clear guidance for HCPs to interpret an adult patient’s risk score and formulate an effective management plan.
Individuals with a high-risk EpiSwitch CST score are at increased probability of experiencing a severe immune response to COVID-19. Such individuals should be counseled on their risk level and may benefit from a mitigation-strategy review to avoid infection. In the event of infection, early use of medications or other interventions are recommended.
Those at average risk should not be construed as having no risk; complications that do not require critical care are possible.
Risk results do not provide information about an individual’s risk of becoming infected. Regardless of risk results, government and local health-department guidelines must be followed to avoid transmitting the virus.
A validated prognostic tool for predicting a severe immune response to COVID-19.
EpiSwitch CST measures six genetic markers to determine risk category. The test was developed using epigenetic data obtained from COVID-19 patients in North America, South America, and Europe.
Are you interested in becoming an EpiSwitch CST testing center or registered healthcare provider?
Contact EpiSwitch CST Customer Service at 888-236-8896 to open an account, request customized EpiSwitch CST Requisition Forms custom-branded for your practice, order EpiSwitch CST processing kits, or request further assistance relating to EpiSwitch CST. We look forward to speaking with you.